ILA Stock Overview
A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Imugene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.03 |
| 52 Week High | AU$0.036 |
| 52 Week Low | AU$0.03 |
| Beta | 3.38 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.7% | 2.8% | 0.9% |
| 1Y | n/a | -14.6% | 5.7% |
Return vs Industry: Insufficient data to determine how ILA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how ILA performed against the German Market.
Price Volatility
| ILA volatility | |
|---|---|
| ILA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ILA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ILA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Leslie Chong | www.imugene.com |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 for gastric cancer; VAXINIA is in phase 1 MAST trial for patients with metastatic or advanced solid tumours; and CHECKvacc oncolytic virotherapy is in phase 1 clinical trial against metastatic triple negative breast cancer.
Imugene Limited Fundamentals Summary
| ILA fundamental statistics | |
|---|---|
| Market cap | AU$373.31m |
| Earnings (TTM) | -AU$89.24m |
| Revenue (TTM) | AU$15.03m |
24.8x
P/S Ratio-4.2x
P/E RatioIs ILA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILA income statement (TTM) | |
|---|---|
| Revenue | AU$15.03m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$15.03m |
| Other Expenses | AU$104.27m |
| Earnings | -AU$89.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -593.63% |
| Debt/Equity Ratio | 0% |
How did ILA perform over the long term?
See historical performance and comparison